BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: DeFilippis EM, Longman R, Harbus M, Dannenberg K, Scherl EJ. Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies. Curr Gastroenterol Rep 2016;18:13. [PMID: 26908281 DOI: 10.1007/s11894-016-0487-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Vieujean S, Caron B, Haghnejad V, Jouzeau JY, Netter P, Heba AC, Ndiaye NC, Moulin D, Barreto G, Danese S, Peyrin-Biroulet L. Impact of the Exposome on the Epigenome in Inflammatory Bowel Disease Patients and Animal Models. Int J Mol Sci 2022;23:7611. [PMID: 35886959 DOI: 10.3390/ijms23147611] [Reference Citation Analysis]
2 Poláková L, Raus V, Cuchalová L, Poręba R, Hrubý M, Kučka J, Větvička D, Trhlíková O, Sedláková Z. SHARP hydrogel for the treatment of inflammatory bowel disease. Int J Pharm 2021;613:121392. [PMID: 34933083 DOI: 10.1016/j.ijpharm.2021.121392] [Reference Citation Analysis]
3 O'Connell L, Winter DC, Aherne CM. The Role of Organoids as a Novel Platform for Modeling of Inflammatory Bowel Disease. Front Pediatr 2021;9:624045. [PMID: 33681101 DOI: 10.3389/fped.2021.624045] [Reference Citation Analysis]
4 Teruel AH, Gonzalez-Alvarez I, Bermejo M, Merino V, Marcos MD, Sancenon F, Gonzalez-Alvarez M, Martinez-Mañez R. New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy. Int J Mol Sci 2020;21:E6502. [PMID: 32899548 DOI: 10.3390/ijms21186502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
5 Miyagawa I, Tanaka Y. Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis. Expert Review of Clinical Immunology 2020;16:199-206. [DOI: 10.1080/1744666x.2019.1706484] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Dumych T, Bridot C, Gouin SG, Lensink MF, Paryzhak S, Szunerits S, Blossey R, Bilyy R, Bouckaert J, Krammer EM. A Novel Integrated Way for Deciphering the Glycan Code for the FimH Lectin. Molecules 2018;23:E2794. [PMID: 30373288 DOI: 10.3390/molecules23112794] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
7 Ferri D, Gaviña P, Parra M, Costero AM, El Haskouri J, Amorós P, Merino V, Teruel AH, Sancenón F, Martínez-Máñez R. Mesoporous silica microparticles gated with a bulky azo derivative for the controlled release of dyes/drugs in colon. R Soc Open Sci 2018;5:180873. [PMID: 30225077 DOI: 10.1098/rsos.180873] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Krammer EM, de Ruyck J, Roos G, Bouckaert J, Lensink MF. Targeting Dynamical Binding Processes in the Design of Non-Antibiotic Anti-Adhesives by Molecular Simulation-The Example of FimH. Molecules 2018;23:E1641. [PMID: 29976867 DOI: 10.3390/molecules23071641] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
9 Duba AS, Mathew SD. The Seronegative Spondyloarthropathies. Primary Care: Clinics in Office Practice 2018;45:271-87. [DOI: 10.1016/j.pop.2018.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
10 Teruel AH, Pérez-Esteve É, González-Álvarez I, González-Álvarez M, Costero AM, Ferri D, Parra M, Gaviña P, Merino V, Martínez-Mañez R, Sancenón F. Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: New approaches for inflammatory bowel diseases treatment. J Control Release 2018;281:58-69. [PMID: 29753956 DOI: 10.1016/j.jconrel.2018.05.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
11 Niu S, Paluszynski J, Bian Z, Shi L, Kidder K, Liu Y. LPS-primed CD11b+ leukocytes serve as an effective carrier of Shiga toxin 2 to cause hemolytic uremic syndrome in mice. Sci Rep 2018;8:3994. [PMID: 29507316 DOI: 10.1038/s41598-018-22327-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A, Chai C, Kim M, Diehl GE, Ajami NJ, Petrosino JF, Zhou XK, Schwartzman S, Mandl LA, Abramowitz M, Jacob V, Bosworth B, Steinlauf A, Scherl EJ, Wu HJ, Simpson KW, Longman RS. IgA-coated E. coli enriched in Crohn's disease spondyloarthritis promote TH17-dependent inflammation. Sci Transl Med 2017;9:eaaf9655. [PMID: 28179509 DOI: 10.1126/scitranslmed.aaf9655] [Cited by in Crossref: 149] [Cited by in F6Publishing: 161] [Article Influence: 29.8] [Reference Citation Analysis]
13 Sivignon A, Bouckaert J, Bernard J, Gouin SG, Barnich N. The potential of FimH as a novel therapeutic target for the treatment of Crohn’s disease. Expert Opinion on Therapeutic Targets 2017;21:837-47. [DOI: 10.1080/14728222.2017.1363184] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]